OSI Tarceva Approval Falls Flat: Wall Street Wants Aggressive Pricing
Executive Summary
OSI's early experience with the launch of Tarceva suggests that managing investor expectations for a new-model breakthrough medicine may be as challenging as demonstrating a survival benefit in lung cancer
You may also be interested in...
Biogen Idec/Elan Tysabri Guaranteed Coverage Under Medicare Part B
Biogen Idec/Elan's once-monthly I.V. formulation of the multiple sclerosis therapy Tysabri guarantees that the product will be covered under Medicare Part B
Tarceva Price Will Be In Bounds, OSI Says: Above Iressa, Below Gleevec
Genentech/OSI will price the EGFR inhibitor Tarceva between AstraZeneca's Iressa and Novartis' Gleevec, OSI CEO Colin Goddard, PhD, said
Avastin, Erbitux Costs Invite Price Controls, Former NCI Deputy Says
The prices set by Genentech and Bristol-Myers Squibb for their recently launched colorectal cancer therapies are an invitation to impose price controls, former Memorial-Sloan Kettering Cancer Center Physician-in-Chief Robert Wittes, MD, wrote in an editorial published by the Washington Post June 15